Puma BiotechnologyCOVID-19 UPDATE

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to

Home About Us Pipeline News Investors Contacts Careers

Final efficacy results of neratinib in HER2-positive hormone receptor-positive early stage breast cancer from the Phase III ExteNET trial have been published in Clinical Breast Cancer. The full manuscript is available below:A Phase II trial evaluating diarrhea management strategies for NERLYNX® tablets, including dose escalation, has been published in the Annals of Oncology.  The full manuscript is available below:
Corporate Fact Sheet

RECENT NEWSEVENTSCLINICAL TRIALS


January 19, 2021 - Puma Biotechnology to Present at the B. Riley Oncology Investor Conference
Read

January 15, 2021 - Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI
Read

January 5, 2021 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Read

January 4, 2021 - Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference
Read

December 11, 2020 - Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS
Read

December 9, 2020 - Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Read

December 9, 2020 - Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020
Read

December 2, 2020 - Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted
Read

November 17, 2020 - Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
Read

November 5, 2020 - Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer
Read

November 5, 2020 - Puma Biotechnology Reports Third Quarter 2020 Financial Results
Read

November 3, 2020 - Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference
Read

October 22, 2020 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read

October 15, 2020 - NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers
Read

October 5, 2020 - Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer
Read




Upcoming Events

Jan. 21, 2021 - B. Riley Oncology Investor Conference
More

Jan. 26-29, 2021 - IASLC 2021 World Conference on Lung Cancers
More



Past Events

Jan. 15-17, 2021 - ASCO 2021 Gastrointestinal Cancers Symposium
More

Jan. 14, 2021 - 39th Annual J.P. Morgan Healthcare Conference
More

Jan. 11, 2021 - H.C. Wainwright VIRTUAL BioConnect Conference
More

Dec. 8-11, 2020 - San Antonio Breast Cancer Symposium
More

Nov. 10, 2020 - Credit Suisse 29th Annual Virtual Healthcare Conference
More

Nov. 5, 2020 - Puma Biotechnology 3Q-2020 Financial Results Conference Call
More

Sept. 15, 2020 - H.C. Wainwright 22nd Annual Global Investment Conference.
More

Puma-Sponsored Trials
Investigator-Sponsored Trials




Annual Report

2019 Annual Report

 Annual Report Archives

Contact

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com

Business Development:
info@pumabiotechnology.com

Investor Relations:
ir@pumabiotechnology.com

Follow Us:





© 2021 Puma Biotechnology, Inc. | Privacy Policy | Legal Notice | Site Map